Riot Platforms is advancing a $5.5 billion data-center project with Anthropic, involving a lease for 910 megawatts at Riot’s Corsicana site. The project financing relies heavily on debt, with Riot expecting lenders to cover 80% to 90% of costs and Riot contributing $500 million to $1.1 billion in cash. Riot has sold over 20,000 Bitcoin this year to fund construction and repay a $200 million loan, holding just 2,418 BTC as of September 30. The lease includes a provision for Riot to pay 12% interest on construction costs, and once operational, Riot anticipates annual rent income of about $1.8 billion over 15 years.
Riot Platforms is the subject, with Pluang market data providing context. For readers following cryptocurrency markets, here is Pluang's snapshot as of Nov 06, 2026 21:21 WIB: Out of 50 major cryptocurrencies, 6 rose and 43 fell. Notable movers include BCH at Rp4.788.016 with a 1-day change of -8.66%, EOS at Rp12.649 up 8.13%, and XLM at Rp2.772 down 6.73%.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
